#####################
# Document Metadata #
#####################
SET DOCUMENT Name = "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-b peptide and s levels: target engagement, tolerability and pharmacokinetics in humans"
SET DOCUMENT Version = "0.1.0"
SET DOCUMENT Authors = "Lingling Xu"
SET DOCUMENT ContactInfo = "charles.hoyt@scai.fraunhofer.de"
SET DOCUMENT Description = "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-b peptide and s levels: target engagement, tolerability and pharmacokinetics in humans by Macccecchini, et al., 2012"

##############
# Namespaces #
##############

# Namespaces hosted on https://github.com/pharmacome/terminology
# --------------------------------------------------------------
DEFINE NAMESPACE CHEBI          AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns"
DEFINE NAMESPACE DRUGBANK       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns"
DEFINE NAMESPACE ECCODE         AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns"
# DEFINE NAMESPACE FB           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/80171ae62cf43aa1fc8a6c326b94537ab342458c/external/fb-names.belns"
DEFINE NAMESPACE HBP   AS URL "https://raw.githubusercontent.com/pharmacome/terminology/3c85897632afa791ac78fb3aa2e392963ab155b1/export/hbp-names.belns"
DEFINE NAMESPACE HGNC           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns"
DEFINE NAMESPACE HGNCGENEFAMILY AS URL "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/external/hgnc.genefamily-names.belns"
DEFINE NAMESPACE GO             AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns"
DEFINE NAMESPACE INTERPRO       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns"
DEFINE NAMESPACE MESH           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/01c9daa61012b37dd0a1bc962521ba51a15b38f1/external/mesh-names.belns"
DEFINE NAMESPACE MGI            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns"
DEFINE NAMESPACE MIRBASE        AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/mirbase-names.belns"
DEFINE NAMESPACE NCBIGENE       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns"
DEFINE NAMESPACE PFAM           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns"
DEFINE NAMESPACE RGD            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/rgd-names.belns"

# Namespaces hosted on https://github.com/sorgerlab/famplex
# ---------------------------------------------------------
DEFINE NAMESPACE FPLX           AS URL "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns"

# Namespaces hosted on https://arty.scai.fraunhofer.de/artifactory/bel/namespace
# ------------------------------------------------------------------------------
DEFINE NAMESPACE CTO            AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/clinical-trial-ontology/clinical-trial-ontology-1.0.0.belns"
DEFINE NAMESPACE DO             AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20170725.belns"
DEFINE NAMESPACE HP             AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns"
DEFINE NAMESPACE SCOMP          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-named-complexes/selventa-named-complexes-20170725.belns"
DEFINE NAMESPACE SFAM           AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-protein-families/selventa-protein-families-20170725.belns"

# Namespaces defined with regular expressions
# -------------------------------------------
DEFINE NAMESPACE DBSNP          AS PATTERN "rs[0-9]+"
DEFINE NAMESPACE TAXONOMY       AS PATTERN "^\d+$"
DEFINE NAMESPACE UNIPROT        AS PATTERN "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\.\d+)?$"
DEFINE NAMESPACE PUBCHEM AS PATTERN "^\d+$"

###############
# Annotations #
###############

# Annotations defined with regular expressions
# --------------------------------------------
DEFINE ANNOTATION Species AS PATTERN "^\d+$"

# Annotations hosted on https://arty.scai.fraunhofer.de/artifactory/bel/annotation
# --------------------------------------------------------------------------------
DEFINE ANNOTATION Anatomy       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno"
DEFINE ANNOTATION CellLine      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno"
DEFINE ANNOTATION CellStructure AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno"
DEFINE ANNOTATION Cell          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno"
DEFINE ANNOTATION Confidence    AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
DEFINE ANNOTATION Disease       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno"
DEFINE ANNOTATION Gender        AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno"
DEFINE ANNOTATION MeSHAnatomy   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
DEFINE ANNOTATION MeSHDisease   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
DEFINE ANNOTATION Subgraph      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno"
DEFINE ANNOTATION TextLocation  AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"


DEFINE ANNOTATION MeasurementType AS LIST {"IC50","plasma concentration","brain concertration", "CSF concentration","dose"}
DEFINE ANNOTATION MeasurementUnits AS LIST {"μM","mg"}
DEFINE ANNOTATION MeasurementRelation AS LIST {"=", "~"}
DEFINE ANNOTATION MeasurementValue AS PATTERN ".*"
DEFINE ANNOTATION MeasurementRangeLower AS PATTERN ".*"
DEFINE ANNOTATION MeasurementRangeUpper AS PATTERN ".*"

DEFINE ANNOTATION Page AS PATTERN ".*"
DEFINE ANNOTATION Figure AS PATTERN ".*"
DEFINE ANNOTATION ArticleCompoundNumber AS PATTERN ".*"

#######################################################################################################################################################################
# Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans #
#######################################################################################################################################################################
SET Citation = {"PubMed", "22791904"}

SET Page = 896
SET Evidence ="A 160 mg dose was associated with an increased incidence of nausea and vomiting (four subjects were nauseous and three vomited)"
SET Figure = 2A
SET ArticleCompoundNumber = 1
SET MeasurementType = "dose"
SET MeasurementUnits ="mg"
SET MeasurementValue =160

a(PUBCHEM:"11249342") -> path(MESH:Nausea)
a(PUBCHEM:"11249342") -> path(MESH:Vomiting)

UNSET {MeasurementValue,MeasurementUnits,MeasurementType,ArticleCompoundNumber,Figure}


SET Evidence ="Posiphen 80 mg was determined as the no observed adverse effect level (table 1)."
SET ArticleCompoundNumber = 1
SET MeasurementType = "dose"
SET MeasurementUnits ="mg"
SET MeasurementValue =80

a(PUBCHEM:"11249342") cnc path(MESH:Nausea)
a(PUBCHEM:"11249342") cnc path(MESH:Vomiting)
UNSET {MeasurementValue,MeasurementUnits,MeasurementType,ArticleCompoundNumber,Page}

SET Evidence ="The four times a day regimen resulted in some accumulation of Posiphen in plasma and accumulation of Posiphen/metabolites in CSF"

SET Page =899
SET Evidence ="Specifically, Posiphen lowered sAPPa and sAPPb levels by 59.9% and 57.7%, respectively, assessed by the AlpaLisa assay, and by 34.1% and 34%, respectively, assessed by the MSD assay, in accordance with Posiphen’s proposed mechanism of action to inhibit APP expression."
SET ArticleCompoundNumber = 1
a(PUBCHEM:"11249342") -| p(HBP:"sAPP-alpha")
a(PUBCHEM:"11249342") -| p(HBP:"sAPP-beta")

SET Evidence ="In addition, Posiphen significantly reduced levels of t-s (74.1%, as assessed by the Innogenetics assay and 46.2%, as assessed by the AlphaLisa assay) and p-s (61%, as assessed by the Innogenetics assay)."
a(PUBCHEM:"11249342") -| p(HGNC:MAPT)
a(PUBCHEM:"11249342") -| p(HGNC:MAPT,pmod(Ph))

SET Evidence =" A significant lowering of pro-inflammatory, C3 (86.9%) and microglial activation markers, MCP-1 (87.5%) and YKL-40 (72.7%), was evident."
a(PUBCHEM:"11249342") -| p(HGNC:C3)
a(PUBCHEM:"11249342") -| p(HGNC:CCL2)
a(PUBCHEM:"11249342") -| p(HGNC:CHI3L1)

SET Evidence ="and the complement control protein, factor H, were unaffected by Posiphen (26.1% and +23.7%, respectively)."
a(PUBCHEM:"11249342") cnc p(HGNC:CFH)

UNSET Page
UNSET Citation
